Cargando…

Clinical Impact of RANK Signalling in Ovarian Cancer

Ovarian cancer (OC) is a gynaecological malignancy with poor clinical outcome and limited treatment options. The receptor activator of nuclear factor-κB (RANK) pathway, activated by RANK ligand (RANKL), critically controls bone metabolism, tumourigenesis and tumour immune responses. Denosumab, a mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wieser, Verena, Sprung, Susanne, Tsibulak, Irina, Haybaeck, Johannes, Hackl, Hubert, Fiegl, Heidelinde, Marth, Christian, Zeimet, Alain Gustave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627676/ https://www.ncbi.nlm.nih.gov/pubmed/31181781 http://dx.doi.org/10.3390/cancers11060791

Ejemplares similares

The miR-34 family and its clinical significance in ovarian cancer
por: Welponer, Hannah, et al.
Publicado: (2020)

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018)

Tumor necrosis factor receptor modulator spermatogenesis‐associated protein 2 is a novel predictor of outcome in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2019)

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Leitner, Katharina, et al.
Publicado: (2020)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome
por: Wolf, Dominik, et al.
Publicado: (2019)

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer
por: Azim, Samira Abdel, et al.
Publicado: (2016)

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers
por: Notaro, Sara, et al.
Publicado: (2016)

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR
por: Notaro, Sara, et al.
Publicado: (2016)

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
por: Schmid, Gabriel, et al.
Publicado: (2016)

A comparison of four technologies for detecting p53 aggregates in ovarian cancer
por: Heinzl, Nicole, et al.
Publicado: (2022)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective
por: Knoll, Katharina, et al.
Publicado: (2021)

AGO Austria recommendations for genetic testing of patients with ovarian cancer
por: Marth, Christian, et al.
Publicado: (2015)

The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents
por: Karbon, Gerlinde, et al.
Publicado: (2021)

Evaluation of Vav3.1 as prognostic marker in endometrial cancer
por: Boesch, Maximilian, et al.
Publicado: (2018)

Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data
por: Steinkasserer, Lena, et al.
Publicado: (2021)

Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 – a Prospective Cohort Trial
por: Azim, Samira Abdel, et al.
Publicado: (2021)

Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer
por: Luger, Anna K., et al.
Publicado: (2020)

Endometroid carcinoma developing in endometriosis over the symphysis pubis()
por: Peer, Michaela, et al.
Publicado: (2013)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Hedgehog Signaling Pathway in Ovarian Cancer
por: Szkandera, Joanna, et al.
Publicado: (2013)

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens
por: Schirmer, Uwe, et al.
Publicado: (2013)

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens
por: Schirmer, Uwe, et al.
Publicado: (2018)

Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients
por: Wolf, Barbara, et al.
Publicado: (2016)

Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer
por: Sobočan, Monika, et al.
Publicado: (2022)

KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients
por: Kammerer, Sarah, et al.
Publicado: (2016)

Targeting Signaling Pathways in Epithelial Ovarian Cancer
por: Smolle, Elisabeth, et al.
Publicado: (2013)

Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy
por: Meraner, Verena, et al.
Publicado: (2012)

Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia
por: Hackl, Hubert, et al.
Publicado: (2017)

High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.
por: Zeimet, A. G., et al.
Publicado: (1997)

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS)
por: Zeimet, Alain G., et al.
Publicado: (2017)

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.
por: Marth, C., et al.
Publicado: (1997)

Dysregulation of Translation Factors EIF2S1, EIF5A and EIF6 in Intestinal-Type Adenocarcinoma (ITAC)
por: Schatz, Christoph, et al.
Publicado: (2021)

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report
por: Lehmann, M., et al.
Publicado: (2023)

High prevalence of side population in human cancer cell lines
por: Boesch, Maximilian, et al.
Publicado: (2016)

Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
por: Braun, Stephan, et al.
Publicado: (2011)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
por: Brawanski, Konstantin R., et al.
Publicado: (2023)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h3ktlddh7jlc2baaba7f9tl4hq